MS-COVID STUDY PAGE

Do You Have Multiple Sclerosis?

You are invited to be involved in a research study to find out if participants receiving ofatumumab (OMB157G) can produce a response to the COVID-19 vaccine.

 

If you are between the ages of 18 and 55 and have been diagnosed with relapsing Multiple Sclerosis (MS), and are starting or currently being treated with ofatumumab, interferon, or glatiramer acetate, you may quality for this voluntary research study.

 

If you are interested in participating or if you would like to refer a family member or friend, we can explain the details of the clinical research study to you. You can then decide whether or not to participate.

 

Qualified participants:

 

• Will continue to receive their standard care
• Must have received either the Pfizer or Moderna COVID-19 vaccine with or without a booster shot, or be willing to receive it
• Will help others with the same medical condition by contributing to medical research

 

Ofatumumab is a medication administered as a subcutaneous (under the skin) injection for relapsing forms of Multiple Sclerosis (MS) in adults. Approximately 88 people in the United States with Relapsing MS are being asked to join this study.

 

You must have received the Pfizer or Moderna COVID-19 vaccine, with or without a booster shot, or be willing to receive it. Vaccine can be obtained through your insurance or a federal or state program in your locality.

If you would like to find out more about this study, please contact our office via the form below.